A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- Sponsors Sorrento Therapeutics
- 04 Oct 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
- 04 Oct 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
- 28 Mar 2018 Treatment of first cohort has been completed and treatment in second cohort is ongoing, according to a Sorrento Therapeutics media release.